RT Journal Article
T1 A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
A1 Utrero Rico, Alberto
A1 Ruiz Ruigómez, María
A1 Laguna Goya, Rocío
A1 Arrieta Ortubay, Estíbaliz
A1 Chivite Lacaba, Marta
A1 González Cuadrado, Cecilia
A1 Lalueza Blanco, Antonio
A1 Almendro Vázquez, Patricia
A1 Serrano, Antonio
A1 Aguado García, José María
A1 Lumbreras Bermejo, Carlos Juan
A1 Paz Artal, Estela Natividad
AB Despite the growing number of patients with persistent symptoms after acute SARS-CoV-2 infection, the pathophysiology underlying long-COVID is not yet well characterized, and there is no established therapy. We performed a deep immune profiling in nine patients with persistent symptoms (PSP), before and after a 4-day prednisone course, and five post-COVID-19 patients without persistent symptoms (NSP). PSP showed a perturbed distribution of circulating mononuclear cell populations. Symptoms in PSP were accompanied by a pro-inflammatory phenotype characterized by increased conventional dendritic cells and augmented expression of antigen presentation, co-stimulation, migration, and activation markers in monocytes. The adaptive immunity compartment in PSP showed a Th1-predominance, decreased naïve and regulatory T cells, and augmentation of the PD-1 exhaustion marker. These immune alterations reverted after the corticosteroid treatment and were maintained during the 4-month follow-up, and their normalization correlated with clinical amelioration. The current work highlights an immunopathogenic basis together with a possible role for steroids in the treatment for long-COVID.
PB MPDI
SN 2227-9059
YR 2021
FD 2021-10-26
LK https://hdl.handle.net/20.500.14352/4651
UL https://hdl.handle.net/20.500.14352/4651
LA eng
NO Utrero Rico, A., Ruiz Ruigómez, M., Laguna Goya, R. et al. «A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID». Biomedicines, vol. 9, n.o 11, octubre de 2021, p. 1540. DOI.org (Crossref), https://doi.org/10.3390/biomedicines9111540.
NO Instituto de Salud Carlos III/Ministerio de Economía, Comercio y Empresa (España)/Fondo Europeo de Desarrollo Regional
NO Comunidad de Madrid
DS Docta Complutense
RD 10 may 2025